Junzhong Lai, Jiadi Liang, Kunsen Chen, Biyun Guan, Zhirong Chen, Linqin Chen, Jiqiang Fan, Yong Zhang, Qiumei Li, Jingqian Su, Qi Chen, Jizhen Lin
Carrimycin (CA), sanctioned by China's National Medical Products Administration (NMPA) in 2019 for treating acute bronchitis and sinusitis, has recently been observed to exhibit multifaceted biological activities, encompassing anti-inflammatory, antiviral, and anti-tumor properties. Despite these applications, its efficacy in sepsis treatment remains unexplored. This study introduces a novel function of CA, demonstrating its capacity to mitigate sepsis induced by lipopolysaccharide (LPS) and cecal ligation and puncture (CLP) in mice models...
March 2024: Chinese Journal of Natural Medicines